• Topbanner

    Company and history

Company and history

Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.

Existing drug therapies generally have a limited effect or are associated with risk of serious adverse events, and there is therefore a considerable patient need for developing better and safer drugs. Inhibition of SK channels, an ion channel with relevance for regulating the heart rhythm, constitute a new and promising principle for the treatment of AF.

Acesion Pharma aims to develop first-in-class SK channel inhibitors as a more efficacious and safe treatment of AF. Equity investors in Acesion Pharma are Novo A/S, Broadview Ventures, SEED Capital and Wellcome Trust. In 2013 Acesion Pharma received 27.9 million DKK (3.7 million EUR) as a Seeding Drug Discovery Award from the Wellcome Trust to fund the development of a novel drug for the acute treatment of AF.